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Number of serum creatinine tests  flagged as AKI All patients (N=16700) 
T2DM         
(N=9417 ) 
Control        
(N=7283) 
Old algorithm ( retrospective tests) 28306 24257 4049 
      SCr ≥ 1.5 x median SCr 365 to 8 days prior to index 20608  17671 2937 
      SCr ≥ 1.5 x lowest SCr in the 7 days prior to index 10170 8536 1634 
      SCr > 26 μmol/L higher than lowest SCr in the 48 hrs prior to index. 12569  10856 1713 
Modified algorithm (retrospective and prospective tests) 40567 34469 6098 
      SCr ≥ 1.5 x median SCr 365 to 8 days prior to index 20608  17671 2937 
      SCr ≥ 1.5 x lowest SCr in the 7 days prior/post index 21205 17782 3423 
      SCr > 26 μmol/L higher than lowest SCr in the 48 hrs prior/post to index. 24577  21220 3357 
      SCr ≥ 1.5 x median SCr 365 to 8 days post to index 16156  13662 2494 
 
Table S1: Number of AKI cases identified using the NHS England algorithm and the modified algorithm broken down by the different 
criteria used in the definition of the AKI case.  









AKI episodes per 1000 person-years   
Un-adjusted Adjusted for age and sex 








All patients (N=16700) 2404 (14.4) 3295 27.7 (26.3-29.2) - 25.5 (24.1-26.9) - 
   Control  (N=7282) 436 (6.0) 543 8.3 (7.6-9.2) 1.0 9.1 (8.2-10.0) 1.0 
   Type 2 diabetes (N=9417) 1968 (20.9) 2752 43.5 (41.0-46.0) 5.2 (4.7-5.8) 39.5 (37.1-42.0) 4.4 (3.9-4.9) 
No CKD (N=11090) 854 (7.7) 1083 13.8 (12.6-15.2) - 16.3 (14.4-18.5) - 
   Control   (N=6032) 195 (3.2) 228 4.1 (3.6-4.8) 1.0 5.5 (4.7-6.5) 1.0 
   Type 2 diabetes (N=5058) 659 (13.0) 855 26.2 (23.6-29.2) 6.4 (5.3-7.6) 30.6 (26.7-35.0) 5.5 (4.6-6.6) 
CKD (N=5610) 1550 (27.6) 2212 55.7 (52.4-59.1) - 56.2 (51.8-61.0) - 
   Control   (N=1251) 241 (19.3) 315 32.1 (27.9-36.8) 1.0 29.7 (25.5-34.6) 1.0 
   Type 2 diabetes (N=4359) 1309 (30.0) 1897 62.7 (58.7-66.9) 2.0 (1.7-2.3) 62.8 (57.8-68.2) 2.1 (1.8-2.5) 
Prior to CKD diagnosis (N=2442) 187 (7.7) 233 22.6 (19.3-26.5) - 24.2 (19.7-29.7) - 
    Control   (N=587) 23 (3.9) 24 8.8 (5.7-13.7) 1.0 9.6 (6.1-15.2)- 1.0 
    Type 2 diabetes (N=1855) 164 (8.8) 209 27.3 (23.1-32.3) 3.1 (1.9-4.9) 29.6 (23.9-36.6) 3.1 (1.9-4.9) 
Post CKD diagnosis  (N=5610) 1415 (25.2) 1979 68.1 (63.9-72.7) - 69.9 (61.4-79.7) - 
    Control   (N=1251) 224 (17.9) 291 41.3 (35.6-47.8) 1.0 38.9 (32.2-47.1) 1.0 
       Type 2 diabetes (N=4359) 1201 (27.6) 1688 75.9 (70.7-81.4) 1.8 (1.6-2.2) 76.5 (67.2-87.2) 2.0 (1.7-2.3) 
 










AKI episodes per 1000 person-years   
Un-adjusted Adjusted for age and sex 








All patients (N=16700) 3550 6384 58.4 (55.8-61.2) - 49.3 (46.9-51.7) - 
   Control  (N=7282) 660 974 15.6 (14.5-16.9) 1.0 15.9 (14.6-17.2) 1.0 
   Type 2 diabetes (N=9417) 2890 5410 92.3 (87.6-97.2) 5.9 (5.4-6.5) 77.9 (73.8-82.2) 4.9 (4.5-5.4) 
No CKD (N=11090) 1091 1572 21.5 (19.7-23.4) - 24.4 (21.8-27.3) - 
   Control   (N=6032) 273 350 6.5 (5.7-7.4) 1.0 8.7 (7.5-10.0) 1.0 
   Type 2 diabetes (N=5058) 818 1222 40.7 (36.8-45.1) 6.3 (5.4-7.4) 45.9 (40.5-52.1) 5.3 (4.5-5.4) 
CKD (N=5610) 2459 4812 129.6 (123.3-136.1) - 
125.8 (117.3-
134.9) - 
   Control   (N=1251) 387 1026 67.5 (60.3-75.5) 1.0 59.2 (52.2-67.2) 1.0 
   Type 2 diabetes (N=4359) 2072 3780 147.5 (139.8-155.6) 2.2 (1.9-2.5) 
141.8 (132.1-
152.2) 2.4 (2.1-2.7) 
Prior to CKD diagnosis (N=2442) 304 422 42.0 (36.9-47.8) - 41.9 (34.8-50.4) - 
    Control   (N=587) 40 52 19.9 (14.5-27.4) 1.0 20.8 (14.8-29.3) 1.0 
    Type 2 diabetes (N=1855) 264 370 49.4 (43.0-56.7) 2.5 (1.8-3.5) 49.7 (41.0-60.4) 2.4 (1.7-3.4) 
Post CKD diagnosis  (N=5610) 2296 4390 160.1 (152.0-168.6) - 
169.8 (152.9-
188.6) - 
    Control   (N=1251) 361 974 85.2 (75.6-96.1) 1.0 83.2 (71.4-97.1) 1.0 
       Type 2 diabetes (N=4359) 1935 3410 181.2 (171.2-191.7) 2.1 (1.9-2.4) 
187.4 (168.8-
207.9) 2.3 (2.0-2.6) 
Table S3. AKI episode incidence rates and rate ratios for AKIs lasting more than 48hrs in the diabetic and non-diabetic groups 
depending on the CKD status. 
Patients' groups  AKI patients            N (%) 
Number of 
AKI episodes 
AKI episodes per 1000 person-years   
Un-adjusted Adjusted for age and sex 








All patients (N=16700) 4620 (27.7) 4800 32.6 (31.7-33.5) - 31.2 (30.2-32.3) - 
   Non diabetic (N=7282) 952 (13.1) 977 13.9 (13.1-14.8) 1.0 15.9 (15.0-17.0) 1.0 
   Type II diabetes (N=9417) 3668 (39.0) 3823 49.6 (48.0-51.2) 3.6 (3.3-3.9) 44.5 (42.8-46.3) 2.8 (2.6-3.0) 
No CKD (N=11090) 1736 (15.7) 1782 17.5 (16.7-18.3) - 22.0 (20.8-23.3) - 
   Non diabetic (N=6032) 481 (8.0) 495 8.3 (7.6-9.1) 1.0 11.7 (10.7-12.8) 1.0 
   Type II diabetes (N=5058) 1255 (24.8) 1287 30.4 (28.8-32.1) 3.7 (3.3-4.0) 35.6 (33.3-38.1) 3.0 (2.7-3.4) 
CKD (N=5610) 2884 (51.4) 3018 66.2 (63.9-68.6) - 60.5 (57.2064.1) - 
   Non diabetic (N=1251) 471 (37.6) 482 44.5 (40.7-48.7) 1.0 36.6 (33.0-40.5) 1.0 
   Type II diabetes (N=4359) 2413 (55.4) 2536 73.0 (70.2-75.8) 1.6 (1.5-1.8) 67.0 (63.2-71.1) 1.8 (1.7-2.0) 
   Prior to CKD diagnosis (N=2442) 156 (6.4) 163 15.1  (12.9-17.6) - 12.6 (9.5-16.7) - 
        Non diabetic (N=587) 25 (4.3) 26 9.5 (6.4-13.9) 1.0 8.2 (5.2-12.8) 1.0 
       Type II diabetes (N=1855) 131 (7.1) 137 17.0 (14.4-20.1) 1.8 (1.2-2.7) 14.4 (10.7-19.4) 1.8 (1.1-2.7) 
   Post CKD diagnosis  (N=5610) 2744 (48.9) 2855 88.2 (79.1085.1) - 77.5 (71.5-84.1) - 
       Non diabetic (N=1251) 448 (35.8) 356 56.4 (51.5-61.9) 1.0 48.6 (43.1-54.8) 1.0 
       Type II diabetes (N=4359) 2296 (53.7) 2399 89.8 (86.3-93.5) 1.6 (1.4-1.8) 84.5 (77.8-91.7) 1.7 (1.6-1.9) 
Table S4. AKI episode incidence rates and rate ratios for AKIs during a hospital admission in the diabetic and non-diabetic groups 
depending on the CKD status. 
 
 
  All patients (N=16700)        IRR (95% CI) 
No CKD (N=11090)a         
IRR (95%CI) 
CKD (N=5610)b                    
IRR (95%) 
T2DM vs Control 3.54 (3.30-3.80) 3.85 (3.44-4.32) 2.01 (1.82-2.22) 
Sex:  Female vs Male 0.98 (0.92-1.05) 0.96 (0.87-1.07) 0.92 (0.86-0.99) 
Age at recruitment: (per 20 year increase) 1.71(1.66-1.76) 1.76 (1.67-1.84) 1.21 (1.16-1.26) 
Comorbidities at recruitment       
     Coronary Artery Disease (CAD) 1.34 (1.24-1.45) 1.28 (1.11-1.47) 1.26 (1.16-1.38) 
     Congestive Heart Failure (CHF) 2.07 (1.80-2.39) 2.24 (1.60-3.14) 1.85 (1.61-2.13) 
     Peripheral Vascular Disease (PVD) 1.88 (1.63-2.17) 2.37 (1.73-3.23) 1.50 (1.30-1.72) 
     Cerebrovascular Disease (CD) 1.63  (1.43-1.85) 1.76 (1.35-2.29) 1.44 (1.26-1.64) 
     Hypertension:  1.45 (1.34-1.56) 1.41 (1.26-1.58) 1.01 (0.91-1.12) 
     Liver Disease (CD) 3.41 (2.60-4.49) 4.58 (2.87-7.31) 2.17 (1.59-2.96) 
a  No CKD at recruitment or during follow-up         
b CKD at recruitment or during follow-up         
 









Model variable (Fixed Effects) 
No CKD at recruitment (N=9460; No Scr =222564) 
T2D (N=4618; No SCr=147698) No diabetes (N=4842; No SCr=74866) Difference 
Estimate P-value Estimate P-value Estimate P-value 
Reference group*: intercept 103.69 (102.65 to 104.72) <0.001 98.38 (97.66 to 99.10) <0.001 5.30 (4.04 to 6.56) <0.001 
                              Time: slope per 1year -0.20 (-0.33 to -0.07) <0.001 -0.33 (-0.42 to -0.23) <0.001 0.13 (-0.03 to 0.29) 0.123 
AKI intercept: pre AKI vs no AKI -1.03 (-1.73 to -0.32) 0.004 -1.98 (-3.08 to -0.88) <0.001 0.95 (-0.35 to 2.26) 0.152 
                         post AKI vs pre AKI 2.68 (0.81 to 4.55) 0.005 5.20 (1.86 to 8.54) 0.002 -2.52 (-6.35 to 1.31) 0.197 
AKI slope :      pre AKI vs no AKI -1.14 (-1.24 to -1.03) <0.001 -0.29 (-0.46 to -0.11) 0.001 -0.85 (-1.05 to -0.65) <0.001 
                         post AKI vs pre AKI -0.29 (-0.59 to 0.01) 0.056 -0.55 (-1.08 to -0.03) 0.038 0.26 (-0.34 to 0.86) 0.396 
Sex intercept only: M vs F 1.32 (0.7 to 1.94) <0.001 -1.04 (-1.65 to -0.42) 0.001 2.36 (1.48 to 3.24) <0.001 
Age intercept: 50 to 64  vs 49 and under  -12.85 (-13.87 to -11.84) <0.001 -9.5 (-10.33 to -8.66) <0.001 -3.36 (-4.68 to -2.04) <0.001 
                          65 to 79  vs 49 and under  -23.71 (-24.74 to -22.68) <0.001 -18.73 (-19.67 to -17.8) <0.001 -4.98 (-6.38 to -3.59) <0.001 
                          80 and above vs 49 and under  -29.09 (-30.97 to -27.21) <0.001 -25.80 (-27.5 to -24.11) <0.001 -3.29 (-5.82 to -0.76) 0.011 
Age slope:       50 to 64  vs 49 and under  -0.32 (-0.46 to -0.18) <0.001 0.05 (-0.06 to 0.17) 0.362 -0.38 (-0.56 to -0.2) <0.001 
                          65 to 79  vs 49 and under  -0.37 (-0.51 to -0.23) <0.001 -0.04 (-0.17 to 0.09) 0.549 -0.33 (-0.52 to -0.14) <0.001 
                          80 and above vs 49 and under  0.01 (-0.28 to 0.3) 0.925 -0.17 (-0.42 to 0.07) 0.162 0.19 (-0.19 to 0.56) 0.331 
Coronary Artery Disease: intercept   -1.02 (-1.83 to -0.21) 0.013 -0.29 (-1.37 to 0.8) 0.607 -0.73 (-2.09 to 0.62) 0.288 
Congestive Heart Failure: intercept -2.05 (-4.23 to 0.13) 0.066 0.78 (-3.3 to 4.85) 0.71 -2.83 (-7.45 to 1.8) 0.231 
Peripheral Vascular Disease: intercept -0.07 (-2.15 to 2.01) 0.948 -2.04 (-5.44 to 1.36) 0.24 1.97 (-2.02 to 5.96) 0.332 
Peripheral Vascular Disease: slope -0.73 (-1.03 to -0.42) <0.001 -0.13 (-0.61 to 0.34) 0.584 -0.59 (-1.16 to -0.03) 0.04 
Cerebrovascular Disease: intercept -2.34 (-3.96 to -0.72) 0.005 0.12 (-2.78 to 3.01) 0.937 -2.45 (-5.77 to 0.86) 0.147 
Hypertension: intercept -1.64 (-2.35 to -0.93) <0.001 -1.05 (-1.77 to -0.33) 0.004 -0.59 (-1.6 to 0.42) 0.251 
Hypertension: slope -0.19 (-0.29 to -0.09) <0.001 0.01 (-0.08 to 0.11) 0.786 -0.21 (-0.34 to -0.07) 0.004 
*Reference group includes: No AKI during follow-up, female, 49 and below, no cardiovascular disease 
Table S6: Parameter estimates of the longitudinal eGFR data analysis for people with and without T2D and no CKD at recruitment 
 
 
Model variable (Fixed Effects) 
CKD at recruitment (N=1432; No Scr =56827) 
T2D (N=1047; No SCr=44299) No diabetes (N=385; No SCr=12528) Difference 
Estimate P-value Estimate P-value Estimate P-value 
Reference groupa: intercept 59.63 (56.53 to 62.74) <0.001 63.99 (58.63 to 69.35) <0.001 -4.35 (-10.55 to 1.84) 0.168 
Time: slope per 1year -0.71 (-1.12 to -0.30) <0.001 0.01 (-0.81 to 0.82) 0.99 -0.71 (-0.20 to 1.63) 0.125 
AKI intercept: pre AKI vs no AKI -3.85 (-5.27 to -2.43) <0.001 -0.99 (-3.45 to -1.46) 0.427 -2.85 (-5.59 to -0.02) 0.049 
                           post AKI vs pre AKI 2.29 (-0.15 to 4.74) 0.066 9.08 (4.35 to 13.8) <0.001 -6.78 (-12.1 to -1.46) 0.013 
AKI slope :        pre AKI vs no AKI -0.79 (-1.05 to -0.52) <0.001 -0.4 (-0.85 to 0.05) 0.079 -0.38 (-0.90 to 0.14) 0.148 
                           post AKI vs pre AKI 0.23 (-0.24 to 0.71) 0.329 -0.84 (-1.73 to 0.06) 0.066 1.07 (0.06 to 2.08) 0.038 
Sex intercept only: M vs F -0.64 (-2.06 to 0.79) 0.381 -2.13 (-4.49 to 0.23) 0.076 1.5 (-1.26 to 4.25) 0.287 
Age intercept: 49 and under vs  50 to 64   -9.11 (-19.6 to 1.38) 0.089 - - - - 
                          65 to 79   vs  50 to 64   -4.91 (-7.33 to -2.49) <0.001 -4.78 (-9.85 to 0.3) 0.065 -0.13 (-5.75 to 5.49) 0.963 
                          80 and above  vs 50 to 64   -8.17 (-10.82 to -5.52) <0.001 -9.04 (-14.29 to -3.79) <0.001 0.87 (-5.02 to 6.75) 0.772 
Age slope:       49 and under  vs  50 to 64 1 (-0.88 to 2.88) 0.297 - - - - 
                          65 to 79   vs  50 to 64   0.37 (-0.05 to 0.79) 0.085 -0.09 (-0.95 to 0.76) 0.831 0.46 (-0.49 to 1.42) 0.339 
                          80 and above  vs 50 to 64 0.58 (0.11 to 1.05) 0.017 0.06 (-0.83 to 0.95) 0.892 0.51 (-0.49 to 1.52) 0.316 
Coronary Artery Disease: intercept   0.04 (-1.64 to 1.72) 0.962 1.42 (-1.56 to 4.39) 0.35 -1.38 (-4.79 to 2.04) 0.429 
Congestive Heart Failure: intercept 1.48 (-2.02 to 4.99) 0.407 -5.5 (-14.56 to 3.57) 0.235 6.98 (-2.74 to 16.7) 0.159 
Congestive Heart Failure: slope -0.86 (-1.49 to -0.22) 0.008 0.01 (-1.62 to 1.63) 0.996 -0.86 (-2.61 to 0.88) 0.332 
Peripheral Vascular Disease: intercept -3.83 (-7.37 to -0.29) 0.034 -0.62 (-7.57 to 6.33) 0.863 -3.21 (-11.01 to 4.59) 0.419 
Peripheral Vascular Disease: slope 0.14 (-0.55 to 0.83) 0.697 0.64 (-0.58 to 1.87) 0.304 -0.5 (-1.91 to 0.9) 0.481 
Cerebrovascular Disease: intercept -0.78 (-3.4 to 1.83) 0.556 -0.28 (-5.09 to 4.54) 0.911 -0.51 (-5.99 to 4.97) 0.855 
Cerebrovascular Disease: slope -0.12 (-0.6 to 0.36) 0.62 -0.7 (-1.6 to 0.2) 0.128 0.58 (-0.44 to 1.59) 0.266 
Hypertension: intercept 0.99 (-1.2 to 3.18) 0.377 -4.61 (-7.86 to -1.35) 0.006 5.59 (1.67 to 9.52) 0.005 
*Reference group includes: No AKI during follow-up, female, 50 to 64, no cardiovascular disease 
Table S7: Parameter estimates of the longitudinal eGFR data analysis for people with and without T2D and no CKD at recruitment. 
 
 
Figure S1: Identifying AKI episodes (red circles) from longitudinal serum creatinine test (a1-d1). 
The different trajectories of AKI episodes (red) during the course of the disease (a2-d2) ranging 
from rapid recovery within seven days (a2) to longer recovery more than seven days and/or 
multiple AKI insults leading to AKD (b2-c2), or irreversible AKI leading to AKD and CKD (d2). 
Cleaning of the eGFR longitudinal data to ascertain CKD status (a3-d3): first AKI flagged eGFR 
values are removed (red circles), then median eGFR is calculated based on the remaining eGFR 



















































































































































01/01/2005 01/01/2015 19/09/2012 10/10/2012 01/01/2005 01/01/2015
AKI 0 1 AKI 0 1 AKI 0 1
a1 a2 a3
b1 b2 b3
c1 c2 c3
d1 d2 d3
